Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Germany Spain
  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

    Not recruiting

    3 1 1
    Belgium Bulgaria Czechia Finland Germany Greece +5
  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

    Not recruiting

    2 1 1 1
    Germany Italy Poland Slovakia Spain
  • Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

    Not recruiting

    2 1 1 1
    Germany Greece Spain
  • Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

    Not recruiting

    2 1 1
    Belgium France Germany Italy
  • Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    France Italy The Netherlands Poland
  • Study on the Effectiveness of Pembrolizumab and Lenvatinib for Patients with Resectable Mucosal Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

    Not recruiting

    2 1 1
    Investigated Drugs:
    Greece Hungary Romania
  • Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    Belgium Denmark France Germany Greece Italy +4
  • Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy Poland Spain